# Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia

> **NCT06772168** · PHASE3 · RECRUITING · sponsor: **CMG Pharmaceutical Co. Ltd** · enrollment: 240 (estimated)

## Conditions studied

- Dyslipidemia
- Type 2 Diabetes

## Interventions

- **DRUG:** CMG190303(Dapagliflozin/Rosuvastatin)
- **DRUG:** Comparator 1: Dapagliflozin/Rosuvastatin placebo
- **DRUG:** Rosuvastatin/Dapagliflozin placebo

## Key facts

- **NCT ID:** NCT06772168
- **Lead sponsor:** CMG Pharmaceutical Co. Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-19
- **Primary completion:** 2026-11-04
- **Final completion:** 2027-02-01
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2026-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06772168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06772168, "Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06772168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*